Agoraphobia following amphetamine withdrawal.
Agoraphobia, now a clinically accepted entity (DSM-III) was first described more than 100 years ago in the psychiatric literature. Recently, it has been considered a syndrome, with phobia, anxiety and depersonalization being the prominent symptoms. Its etiology is not clear and different schools of thought have given different explanations for its causation. Few reports of recent origin have have described a close association between the intake and/or discontinuation of pharmacologic agents and the onset of the syndrome. The agents implicated were the tricyclic group. Our report describes another "antidepressant," d-amphetamine, which when discontinued by our patient, was followed by the full syndrome of agoraphobia.
D000328:Adult; D000379:Agoraphobia / Q000209:etiology* / Q000523:psychology; D000661:Amphetamine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D009765:Obesity / Q000188:drug therapy; D010698:Phobic Disorders / Q000209:etiology*; D013375:Substance Withdrawal Syndrome / Q000523:psychology*; D019966:Substance-Related Disorders / Q000523:psychology
D000661:Amphetamine